- Home
- ASTC vs BIAF Comparison
ASTC vs BIAF Comparison
Compare ASTC & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASTC | BIAF |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | 57 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASTC | BIAF |
|---|---|---|
| Price | $2.31 | $1.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 56.8K | ★ 319.7K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2600.00 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.92 | $0.23 |
| 52 Week High | $8.01 | $13.50 |
Technical Indicators
Market Signals| Indicator | ASTC | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 32.59 | 32.66 |
| Support Level | $2.25 | $1.23 |
| Resistance Level | $2.45 | $1.79 |
| Average True Range (ATR) | 0.16 | 0.18 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 6.80 | 20.99 |
Price Performance
Historical ComparisonAbout ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.